ClinicalTrials.gg
CompletedNCT03479372Updated Jul 9, 2019

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

A Phase 1/2 interventional study of PAN-90806 Ophthalmic Suspension in Neovascular Age-related Macular Degeneration, sponsored by PanOptica, Inc.. Completed at 18 sites in 5 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by PanOptica, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
252nd of 491
51 · median 55
Started
2018
with 29 others
Phase 1/2
61 of 645
7 open now
Registered
385th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 252nd largest by enrollment of the 491 interventional ones that give a count, is one of 30 that started in 2018, is one of 61 in phase 1/2, and was the 385th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Double-masked, uncontrolled, multi-center, study in which participants will be randomized to one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.

Read the detailed description

Patients with newly diagnosed, active, pathologic CNV associated with neovascular AMD will be screened for inclusion into the study after providing written informed consent. Participants who are eligible for the study will be centrally randomized at Day 1 to one of three doses of PAN-90806 Eye Drops. Participants will be instructed to apply one drop of PAN-90806 to the ocular surface of the identified study eye once daily for twelve (12) weeks.

Participants will return for follow-up visits at Week 2, Week 4, Week 8, Week 12, 1 week after stopping PAN-90806 treatment and 1 month after stopping PAN-90806 treatment.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • AMD
  • wet AMD
  • exudative AMD
  • macular degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD
  • Aged 50 years or older
  • Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye

Exclusion criteria

Exclusion Criteria:

  • Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye
  • Prior use within the last 3 months or a high possibility of requiring treatment with anti-VEGF therapy in the fellow eye during the study
  • Significant retinal serous pigment epithelial detachment (PED), atrophy, or fibrosis/scar involving the fovea
  • History of or current clinical evidence in the study eye of aphakia, diabetic macular edema, any ocular inflammation or infections, pathological myopia, retinal detachment, advanced glaucoma, and/or significant media opacity, including cataract
  • History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening
  • Uncontrolled hypertension despite use of antihypertensive medications
  • Participation in any drug or device study, systemic or ocular, within past 3 months
  • Women who are pregnant or nursing
  • Women of who are not using a highly effective form of
  • Known serious allergies or to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    PAN-90806 Eye Drops, dose 1

    PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks

    Drug: PAN-90806 Ophthalmic Suspension

  • Experimental
    PAN-90806 Eye Drops, dose 2

    PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks

    Drug: PAN-90806 Ophthalmic Suspension

  • Experimental
    PAN-90806 Eye Drops, dose 3

    PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks

    Drug: PAN-90806 Ophthalmic Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events

    Time frame: up to 12 weeks

Secondary outcomes

  1. Mean change from baseline in study eye ETDRS Visual Acuity

    Time frame: through Week 12

  2. Mean change from baseline in study eye retinal thickness

    Time frame: through Week 12

  3. Number of patients needing additional treatment with ranibizumab

    Time frame: through Week 12

07

Study locations

18 sites
  • Colorado Retina Associates
    Golden, Colorado 80401, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Retinal Consultants of Nevada
    Henderson, Nevada 89052, United States
  • Retinal Consultants of Nevada
    Las Vegas, Nevada 89144, United States
  • Retina Center of New Jersey
    Bloomfield, New Jersey 07003, United States
  • Retina Center of New Jersey
    Teaneck, New Jersey 07666, United States
  • Vision Research Center
    Albuquerque, New Mexico 87109, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Fakultní nemocnice Královské Vinohrady
    Praha, 100 34, Czechia
  • Axon Clinical
    Praha, 150 00, Czechia
  • Semmelweis University
    Budapest, 1085, Hungary
  • University of Debrecen
    Debrecen, 4032, Hungary
  • P. Stradina Clinical University hospital
    Riga, LV1002, Latvia
  • Barnet Hospital
    Barnet, Hertfordshire EN5 3DJ, United Kingdom
  • New Cross Hospital
    Wolverhampton, West Midlands WV10 0QP, United Kingdom
  • Bradford Royal Infirmary
    Bradford, BD9 6RJ, United Kingdom
  • Moorefields Eye Hospital
    London, EC1V 2PD, United Kingdom
  • Manchester Royal Eye Hospital
    Manchester, M13 9WL, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in May 2019, 13 months.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2018
First posted
Mar 27, 2018
StartActual
Apr 26, 2018
Primary completionActual
May 27, 2019
CompletionActual
Jun 27, 2019
Last update
Jul 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03479372
Lead sponsor
PanOptica, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Apr 26, 2018
Primary completion
May 27, 2019
Completion
Jun 27, 2019
Last update
Jul 9, 2019

Study contacts

Martin Wax, MD
study director · PanOptica, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cp-547632

Start the discussion